CJC-1295 Stacking Guide: Best Combinations & Protocols (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Stacking
CJC-1295 is frequently combined with other peptides to enhance its effects.
CJC-1295 + Ipamorelin
This is the most popular combination. Ipamorelin is a growth hormone secretagogue that works through the ghrelin receptor, providing a complementary mechanism to CJC-1295's GHRH pathway. Together, they produce synergistic GH release greater than either peptide alone. Typical dosing involves 100–300 mcg of each peptide administered together. See the full CJC-1295 vs ipamorelin comparison for more detail.
CJC-1295 + GHRP-6 or GHRP-2
These growth hormone-releasing peptides also work through the ghrelin pathway and can be stacked with CJC-1295. GHRP-6 notably increases appetite, which may be beneficial for those seeking to gain mass. For a comparison of these two GHRPs, see GHRP-2 vs GHRP-6.
CJC-1295 + BPC-157
Some users combine CJC-1295 with BPC-157 for enhanced recovery and healing, though this combination lacks clinical research.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005.
Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009.
Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011.
Aidsmap. Lipodystrophy study halted after patient death. 2006.
World Anti-Doping Agency. The 2024 Prohibited List International Standard.
FDA. CJC-1295 - Pharmacy Compounding Advisory Committee Materials. December 2024.
Hone Health. Everything You Need to Know About the FDA Peptide Ban.
Innerbody. CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice.